• AI^HUMAN

    We Invest in Breakthrough Technologies Linked to Artificial Intelligence

  • AI^Human™ is an early stage VC fund investing in breakthrough technologies linked to Artificial Intelligence. We specialise in companies that generate, control and learn from unique data sources. Sectors include Healthcare, Life Sciences, AgTech, Automation, FoodTech, FinTech and EduTech.

     

    Our focus extends to companies with hardware applications, including robotics, computer vision, sensor networks and drones, and companies with deep technologies that improve AI performance. We also look generally at companies that have new AI-enabled business models that are transforming industries.

     

    The AI^Human fund is backed by Japanese & other global firms who are providing an anchor of $AU10M, targeting a fund size of $AU200M. These global anchors value the rapid growth strategy of the fund: Australian companies that are US similar, at superb value, with unique IP, comprehensive access to deals, co-investment, Japanese uplift, Asian uplift, and global exits. First close is expected in Q3, 2018. At least 80% of capital will be deployed in Australia.

     

    Australian AI is World Class. The universities are amongst the very best and boast one of the world’s highest acceptance rates for academic papers in AI. There are a plethora of excellent companies whose valuations are more attractive than China or Silicon Valley. These companies often receive large non-dilutionary grants & rebates.

     

    The AI^Human fund is registered in Victoria. The Fund Manager is InterValley Ventures P/L, registered in Queensland. Queensland is particularly strong in AI ventures, including agricultural robotics. This is reflected in their strategic alliance with Softbank.

  • Global Team Members

    Jun Hosoya

    General Partner
    Japan

    Jun Hosoya has more than 30 years of investment and management experience across Japan and the USA, including 46 venture investments. His many successful exits include 8 IPO’s, 6 M&A transactions and 3 trade sales.

     

    Jun was the founding member and Managing Director of INCJ (Innovation Network Corporation) in 2009, a Japanese VC fund with an AUM of USD 20 billion. At INCJ Jun was responsible for investment and management of early stage innovation companies. Jun also launched the Life Science IP Fund and MedVenture Partners, an incubation fund for medical devices.

     

    Prior to INCJ, Jun was a Partner for Apax Globis, a VC fund in Tokyo, where he led the Technology Investment Team. Prior to that Jun was International Portfolio Manager for NED, responsible for managing investments in Silicon Valley.

     

    Jun has served as COO and has been a board director for numerous portfolio companies in early stage, pre-IPO and post-IPO stages.

     

    Education:

    MBA, University of Chicago; BA, Rikkyo University

     

    Simon Wright

    General Partner
    Asia Pacific & Europe

    From the UK, Simon Wright has extensive experience within entrepreneurial environments. For more than twenty years he held CEO positions within the Virgin Group working closely with Sir Richard Branson and was a member of the Investment Committee for the Group.

     

    As well as working alongside many entrepreneurs, Simon also brings extensive deal experience having directly managed exits over USD$1bn in value with Virgin. Since then Simon has worked with some of the largest Private Equity firms in the Europe and the USA, and recently worked with Bridgepoint Capital on a USD1.1bn exit, achieving a 2.5x return in less than two years.

     

    Simon is based in Melbourne, Australia. Having started, grown and exited businesses in all parts of the world this gives him perspective on requirements to successfully globalise businesses.

     

    Simon has worked on Boards across a range of sectors allowing him to work effectively with portfolio companies.

     

    Education:

    Sheffield Business School, Finance; Chartered Institute (ACMA); GAICD

     

    Richard Lawson

    Partner
    Australia

    Richard Lawson is an investor and data scientist with a deep background as quantitative investor and researcher. Throughout his career he has specialised in the application of artificial intelligence to managing investments within capital markets.

     

    Richard has extensive experience implementing the quant-data pipeline and building multi-factor quantitative stock selection models in a global setting. Richard started his career on the sell side at top tier firms such as JPMorgan and Macquarie, then broadened to funds management and hedge funds.

     

    At Schroder Investment, Richard was in a team managing more than USD 40 billion. His role was to invest in globally listed companies based on mathematical models of company and industry characteristics. Richard lectures at Macquarie University on quantitative investing and quantitative techniques for deal evaluation.

     

    Education:

    BSc (Hons), University of Sydney; MCom (Funds Mgmt), University of New South Wales; MAICD
     

    Yasushi Kuroda

    Venture Partner
    Japan & Australia

    Yasu Kuroda has more than 15 years experience in venture investment and venture incubation. His portfolio includes 10 high-tech ventures. Yasu’s successful exits include 1 IPO and 4 M&A’s, with other investments still running. He was previously Deputy General Manager of Mitsui Sumitomo Insurance Venture Capital, a USD 200 million VC.

     

    Yasu has a strong background in leadership development, coaching, and organizational development, which he now brings to his role as an investor. He has served as board director for numerous early stage companies. Leveraging his HR skills, Yasu has engaged in value-add and turnaround strategies for various portfolio companies. He was instrumental in core hires & building the management team of the company that has already gone to IPO.

     

    Yasu is married to an Australian. He has a solid network within Australia’s innovation ecosystem including with Austrade, local VC’s and as a member of the expert network for the government scheme ‘Accelerating Commercialisation’.

     

    Education:

    MBA, University of Pennsylvania; BA, Keio University

    Doron Ben-Meir

    Venture Partner and Chairman of the Investment Committee
    Australia

    As founding CEO of Commercialisation Australia (now Accelerating Commercialisation), Doron contributed to incubating over 500 seed to early stage ventures in a unique, government led ecosystem. He is highly regarded in Australia and beyond.


    Doron Chairs University of Melbourne Commercial Ltd and is a Board member of the NASDAQ Entrepreneurial Center in San Francisco, California. Doron was also a member of the Federal Government’s Entrepreneur Program Committee which makes recommendations for funding under Accelerating Commercialisation and other programs. His continuous involvement in the program spanned seven years, from conception to maturity.


    Prior to these positions, Doron spent 20 years as a venture capitalist and serial entrepreneur. He received a B.Sc (Math and Physics) and B.E (Electronics and Computer Science Hons) from Monash University and is a Graduate Member of the Australian Institute of Company Directors.
    Doron is chairman of InterValley’s Investment Committee.

     

    Education:

    BSc, Monash University; BEng (Hons), Monash University

    * “Past performance is not a reliable indicator of future performance”.

  • ADVISORS

    Professor Toby Walsh

    Toby Walsh is Scientia Professor of Artificial Intelligence at the University of New South Wales, research group leader at Data61, guest Professor at Technical University of Berlin, external Professor of the Department of Information Science at Uppsala University and an honorary fellow of the School of Informatics at Edinburgh University. He is a fellow of the Australian Academy of Science, the Association for the Advancement of Artificial Intelligence and the European Coordinating Committee for AI

    Professor Fabio Ramos

    Fabio Ramos is an Professor in machine learning and robotics at the School of Information Technologies, and co-director of the Centre for Translational Data Science at the University of Sydney. He has over 130 peer-reviewed publications and received numerous best paper awards. His research focuses on statistical machine learning techniques for large-scale data fusion with applications in robotics, mining, environmental monitoring and healthcare

    John Lee, M.D.

    John Tsung-Chun Lee, M.D. is a Taiwanese physician scientist turned entrepreneur in medical technologies, trained in Taiwan (NTU), Japan (Keio), and US (Stanford/Silicon Valley). John teaches Medtech, Biodesign & entrepreneurship at major Taiwanese universities.

  • FIEA Article 63:

     

    日本国内の投資家の皆様へ:
    本ファンドは金融商品取引法第63条に基づく「適格機関投資家等特例業務」に関する特例の適用を受けています。適格機関投資家等特例業務に関する公衆縦覧【法第63条第6項】はこちらのリンクからご覧頂けます。Form 20-2 [Japan]

     

    For Investors in Japan:

    InterValley Ventures Pty Ltd has filed the Notification for Specially Permitted Businesses for Qualified Institutional Investors, etc. (SPBQII) to the Financial Services Agency of Japan pursuant to Article 63 of the Financial Instruments and Exchange Act (FIEA). Public Inspection Regarding Specially Permitted Businesses for Qualified Institutional Investors, etc. [FIEA Article 63(6)] is available at the following link: Form 20-2 [Japan]

    Important Information:

     

    Important Information: This material was created by InterValley Ventures Pty Ltd ACN 620 419 123 (General Partner). InterValley Ventures Pty Ltd is a Corporate Authorised Representative (CAR: 1265243 of Affirmative Financial Services Pty Ltd who holds an Australian Financial Services Licence (AFSL: 331840). This material is for information purposes only and should not be construed as an offer or solicitation or recommendation to buy or sell any financial products. The information in this presentation or communication is directed and available to residents of Australia only deemed to be Wholesale Clients under Section 761G of the Corporations Act of 2001. This material is neither a prospectus nor a disclosure document under the Corporations Act 2001 (Cth) (Act), nor is it required to be. A copy is not required to be, and has not been, lodged with the Australian Securities and Investments Commission. This material has been prepared only for issue to and use by prospective investors who qualify as Wholesale Investors as defined in the Act (Wholesale Investors) and is not intended to be received or read by anyone other than a Wholesale Investor. An interest in AI^Human, LP (Fund) will only be issued to investors that are Wholesale Investors.


    Jurisdiction: This material does not constitute, and may not be used for the purpose of, an offer or solicitation in any jurisdiction other than the Commonwealth of Australia or in circumstances in which such offer or solicitation is not authorised other than as set out in the separate international disclosure statement. No recipient of this material in any jurisdiction other than the Commonwealth of Australia may treat it as constituting an invitation to them to apply for an interest in the Fund unless, in the relevant jurisdiction, such an invitation could lawfully be made to that recipient or the Application Form in the separate AI/HUMAN, LP Information Memorandum could lawfully be used in compliance with applicable law.


    Confidentiality: This material is the property of the General Partner. By receiving this material, the recipient agrees to keep its content confidential and agrees not to copy, supply, disseminate or disclose any information in relation to its content without the prior written consent of the General Partner.


    General advice: This information is intended to be general in nature and is not personal financial product advice. Any advice contained in this document is general advice only and has been prepared without considering your objectives, financial situation or needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. You should seek independent financial advice and read the relevant disclosure statements or other offer document prior to making an investment decision (including a decision about whether to acquire or continue to hold) about a financial product. The General Partner makes no representation to the recipient or advisers (as relevant) as to, or in relation to, the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this material or any omission from this material or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, prospects or financial returns and nothing in this material is or should be relied upon as a promise or representation as to the future. The General Partner expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Fund contained in this material or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this material, the General Partner undertakes no obligation to provide any additional information other than as specifically stated in this material.


    Forward looking statements: This material contains forward looking statements which are identified by words such as “may”, “could”, “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans” and other similar words that involve risks and uncertainties. These forward looking statements are subject to various factors that could cause the results of the Fund to differ materially from those expressed or anticipated in these statements. The General Partner does not intend to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this material, except where required by law.


    Investment risk warning: Investment in the Fund involves a high level of risk and is not suitable for investors who are unable to sustain the loss of all or part of the sum invested, or who require predictable levels of return or liquidity. Section 6 of the separate InterValley AI/HUMAN, LP Information Memorandum sets out additional risks of an investment in the Fund. Potential investors should assess their own appetite for such risks independently and consult their own advisors before making a decision to invest in the Fund. Investment in the Fund should be regarded as speculative and is subject to the conflicts of interest described in the separate Information Memorandum. Investments should be considered only by wholesale investors.